Healthcare / Drug Manufacturers - Specialty & GenericBSE
$234.00
-14.00 (-5.36%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $30.0M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.3B
P/E
44.2x
↑EV/EBITDA
37.6x
↑ROE
-1.8%
↓Gross Margin
38.2%
↓Debt/Equity
0.68
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-7.3%
FCF CAGR
—
FCF margin
-6.8%
FCF / Net income
8.37x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.59B · net income $-12.9M · FCF $-108.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.59B | $1.59B | $1.97B | $1.83B | $2.00B |
| Net Income | $-12.9M | $-12.9M | $1.4M | $-1.8M | $11.4M |
| EBITDA | $71.5M | $71.5M | $112.5M | $75.0M | $81.5M |
| EPS | -2.97 | -2.97 | 0.17 | -0.23 | 1.43 |
| Gross Margin | 38.2% | 38.2% | 37.1% | 15.8% | 16.9% |
| Operating Margin | 1.5% | 1.5% | 3.0% | -1.5% | 2.1% |
| Net Margin | -0.8% | -0.8% | 0.1% | -0.1% | 0.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.68 | 0.68 | 1.27 | 1.13 | 0.88 |
| Cash Flow | |||||
| Free Cash Flow | $-108.0M | $-108.0M | $30.0M | $48.8M | $-34.2M |
| Returns | |||||
| ROE | -1.8% | -1.8% | 0.3% | -0.4% | 2.4% |
| Valuation | |||||
| P/E | 44.23 | 44.23 | 752.94 | — | 150.38 |
| EV/EBITDA | 37.62 | 37.62 | 14.46 | 17.31 | 26.06 |
| P/B | 3.25 | 3.25 | 2.29 | 1.69 | 3.68 |
| Growth & Yield | |||||
| Revenue Growth | -19.1% | -19.1% | 7.8% | -8.5% | — |
| EPS Growth | -1847.1% | -1847.1% | 173.9% | -116.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-45.0%
Start / end P/E
n/dx → n/dx
EPS bridge
0.17 → -2.97
Residual
-45.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.